Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
January 2023
in “
Cutis
”
Studysummary This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on cdn.mdedge.com →